




Name	Daisuke Tomizawa, M.D., Ph.D.	
Current Position	Head, Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan	
Country	Japan	
Major Field	Pediatric leukemia; especially, AML, infant ALL	

Educational Background

M.D.: Tokyo Medical and Dental University (TMDU), 1999
Ph.D.: TMDU, 2010

Professional Experience

1999-2000: Junior Resident, Pediatrics, Univ. Hospital of Med., TMDU; Tokyo
2000-2001: Junior Resident, Pediatrics, Japan Red Cross Medical Center; Tokyo
2001-2003: Medical Fellow, Pediatrics, Univ. Hospital of Med., TMDU; Tokyo
2003-2004: Senior Resident, Ped Hematol/Oncol, Saitama Children's Medical Center; Saitama
2004-2006: Assist. Prof., Pediatrics & Dev. Bio., TMDU; Tokyo
2010-2014: Assist. Prof., Pediatrics, Univ. Hospital of Med., TMDU; Tokyo
2014-2018: Chief, Leukemia & Lymphoma, Children's Cancer Center, National Center for Child Health & Dev. (NCCHD); Tokyo
2018-Present: Head, Leukemia & Lymphoma, Children's Cancer Center, NCCHD; Tokyo

Other Experience and Professional Memberships

Professional society membership:

- Japan Pediatric Society (JPS)
- Japanese Society of Pediatric Hematology/Oncology (JSPHO)
- Japanese Society of Hematology (JSH)
- Japan Society for Transplantation and Cellular Therapy (JSTCT)
- Japanese Society of Medical Oncology (JSMO)
- American Society of Hematology (ASH)
- International Society of Pediatric Oncology (SIOP)

Cooperative group activities:

Japan Children's Cancer Group (JCCG) / Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)

- Infant leukemia committee, 2003-Present (Chairman, 2012-2016)
- AML committee, 2016-Present (Vice chairman, 2010-2019; Chairman 2019-Present)

Tokyo Children's Cancer Study Group (TCCSG)

- Chairman, 2019-Present

International BFM Study Group (I-BFM-SG), AML Committee

Children's Oncology Group, International member, 2009-Present

- Steering Committee Member, International Affairs Committee, 2021-Present

Pediatric Cancer Data Commons (PCDC)

- Executive Committee Member and Co-chair, INTERACT (AML disease consortia), 2021-Present
- Member and Co-chair, Scientific Advisory Committee, 2021-Present



Main Scientific Publications

1. Tomizawa D, Miyamura T, Imamura T, Watanabe T, Moriya Saito A, Ogawa A, Takahashi Y, Hirayama M, Taki T, Deguchi T, Hori T, Sanada M, Ohmori S, Haba M, Iguchi A, Arakawa Y, Koga Y, Manabe A, Horibe K, Ishii E, Koh K. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. *Blood*. 2020 Oct 15;136(16):1813-1823. doi: 10.1182/blood.2019004741. PMID: 32845001.
2. Tomizawa D, Yoshida M, Kondo T, Miyamura T, Taga T, Adachi S, Koh K, Noguchi M, Kakuda H, Watanabe K, Cho Y, Fukuda T, Kato M, Shiba N, Goto H, Okada K, Inoue M, Hashii Y, Atsuta Y, Ishida H. Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. *Bone Marrow Transplant*. 2019 Mar;54(3):393-401. doi: 10.1038/s41409-018-0273-7. Epub 2018 Jun 29. PMID: 29959436.
3. Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, Taga T, Fukuda T, Goto H, Inagaki J, Koh K, Ohashi K, Ozawa Y, Inoue M, Kato K, Tanaka J, Atsuta Y, Adachi S, Ishida H. Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. *Biol Blood Marrow Transplant*. 2017 Sep;23(9):1515-1522. doi: 10.1016/j.bbmt.2017.05.009. Epub 2017 May 10. PMID: 28501543.
4. Tomizawa D, Watanabe T, Hanada R, Horibe K, Horikoshi Y, Iwamoto S, Kinoshita A, Moritake H, Nakayama H, Shimada A, Taga T, Takahashi H, Tawa A, Terui K, Hori H, Kawano Y, Kikuta A, Manabe A, Adachi S. Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. *Int J Hematol*. 2015 Sep;102(3):318-26. doi: 10.1007/s12185-015-1825-x. Epub 2015 Jul 1. PMID: 26126642.
5. Koh K, Tomizawa D, Moriya Saito A, Watanabe T, Miyamura T, Hirayama M, Takahashi Y, Ogawa A, Kato K, Sugita K, Sato T, Deguchi T, Hayashi Y, Takita J, Takeshita Y, Tsurusawa M, Horibe K, Mizutani S, Ishii E. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. *Leukemia*. 2015 Feb;29(2):290-6. doi: 10.1038/leu.2014.172. Epub 2014 Jun 3. PMID: 24888273.
6. Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Kigasawa H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S. Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. *Leukemia*. 2013 Dec;27(12):2413-6. doi: 10.1038/leu.2013.153. Epub 2013 May 16. PMID: 23677335.
7. Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Kiyokawa N, Isoyama K, Mizutani S, Hara J, Horibe K, Nakahata T, Adachi S. Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. *Int J Hematol*. 2013 Nov;98(5):578-88. doi: 10.1007/s12185-013-1429-2. Epub 2013 Sep 26. PMID: 24068655; PMCID: PMC7101778.
8. Tomizawa D, Koh K, Hirayama M, Miyamura T, Hatanaka M, Saikawa Y, Ishii E. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group. *Pediatr Blood Cancer*. 2009 Jul;52(7):808-13. doi: 10.1002/pbc.21975. PMID: 19229974.
9. Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, Kosaka Y, Oda T, Oda M, Hayashi Y, Eguchi M, Horibe K, Nakahata T, Mizutani S, Ishii E. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. *Leukemia*. 2007 Nov;21(11):2258-63. doi: 10.1038/sj.leu.2404903. Epub 2007 Aug 9. PMID: 17690691.
10. Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. *Pediatr Blood Cancer*. 2007 Aug;49(2):127-32. doi: 10.1002/pbc.20944. PMID: 16807916.